Warning! GuruFocus detected
1 Medium warning sign
with 4559.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Zeria Pharmaceutical Co Ltd
ISIN : JP3428850006
Share Class Description:
TSE:4559: Ordinary SharesDescription
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.56 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.52 | |||||
Debt-to-EBITDA | 3.16 | |||||
Interest Coverage | 23.04 | |||||
Piotroski F-Score | 9/9 | |||||
Altman Z-Score | 2.23 | |||||
Beneish M-Score | -2.44 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.5 | |||||
3-Year EBITDA Growth Rate | 28.5 | |||||
3-Year EPS without NRI Growth Rate | 41.7 | |||||
3-Year Book Growth Rate | 13.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 16.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.31 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.84 | |||||
9-Day RSI | 54.49 | |||||
14-Day RSI | 53.45 | |||||
3-1 Month Momentum % | 1.68 | |||||
6-1 Month Momentum % | -5.1 | |||||
12-1 Month Momentum % | 8.34 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 0.91 | |||||
Cash Ratio | 0.43 | |||||
Days Inventory | 243.8 | |||||
Days Sales Outstanding | 104.49 | |||||
Days Payable | 60.83 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.03 | |||||
Dividend Payout Ratio | 0.26 | |||||
3-Year Dividend Growth Rate | 9 | |||||
Forward Dividend Yield % | 2.03 | |||||
5-Year Yield-on-Cost % | 2.67 | |||||
3-Year Average Share Buyback Ratio | 1.2 | |||||
Shareholder Yield % | 6.4 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 72.78 | |||||
Operating Margin % | 12.57 | |||||
Net Margin % | 9.12 | |||||
FCF Margin % | 10.03 | |||||
ROE % | 9.09 | |||||
ROA % | 4.87 | |||||
ROIC % | 5.63 | |||||
3-Year ROIIC % | 84.79 | |||||
ROC (Joel Greenblatt) % | 20.78 | |||||
ROCE % | 10.28 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 13.25 | |||||
Forward PE Ratio | 9.88 | |||||
PE Ratio without NRI | 13.29 | |||||
Shiller PE Ratio | 21.3 | |||||
PEG Ratio | 0.72 | |||||
PS Ratio | 1.21 | |||||
PB Ratio | 1.17 | |||||
Price-to-Tangible-Book | 2.24 | |||||
Price-to-Free-Cash-Flow | 12.06 | |||||
Price-to-Operating-Cash-Flow | 8.19 | |||||
EV-to-EBIT | 11.7 | |||||
EV-to-EBITDA | 8.57 | |||||
EV-to-Revenue | 1.45 | |||||
EV-to-FCF | 14.01 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 0.81 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.47 | |||||
Price-to-Graham-Number | 1.15 | |||||
Earnings Yield (Greenblatt) % | 8.53 | |||||
FCF Yield % | 8.3 | |||||
Forward Rate of Return (Yacktman) % | 20 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zeria Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 82,579.281 | ||
EPS (TTM) (円) | 170.93 | ||
Beta | 0.27 | ||
3-Year Sharpe Ratio | 0.38 | ||
3-Year Sortino Ratio | 0.56 | ||
Volatility % | 18.26 | ||
14-Day RSI | 53.45 | ||
14-Day ATR (円) | 62.729243 | ||
20-Day SMA (円) | 2254.25 | ||
12-1 Month Momentum % | 8.34 | ||
52-Week Range (円) | 1921 - 2505 | ||
Shares Outstanding (Mil) | 44.08 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zeria Pharmaceutical Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zeria Pharmaceutical Co Ltd Stock Events
Event | Date | Price (円) | ||
---|---|---|---|---|
No Event Data |
Zeria Pharmaceutical Co Ltd Frequently Asked Questions
What is Zeria Pharmaceutical Co Ltd(TSE:4559)'s stock price today?
The current price of TSE:4559 is 円2264.00. The 52 week high of TSE:4559 is 円2505.00 and 52 week low is 円1921.00.
When is next earnings date of Zeria Pharmaceutical Co Ltd(TSE:4559)?
The next earnings date of Zeria Pharmaceutical Co Ltd(TSE:4559) is .
Does Zeria Pharmaceutical Co Ltd(TSE:4559) pay dividends? If so, how much?
The Dividend Yield %  of Zeria Pharmaceutical Co Ltd(TSE:4559) is 2.03% (As of Today), Highest Dividend Payout Ratio of Zeria Pharmaceutical Co Ltd(TSE:4559) was 0.86. The lowest was 0.26. And the median was 0.53. The  Forward Dividend Yield % of Zeria Pharmaceutical Co Ltd(TSE:4559) is 2.03%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |